Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Impact of Extranodal Disease Involvement on Outcomes in Post-Transplant Lymphoproliferative Disorder

Megan Melody, Frederique St. Pierre, Irene Helenowski, William B Pearse, Chetan V Vakkalagadda, Joseph R. Leventhal, John Friedewald, Bing Ho, Daniel Ganger, Jane N. Winter, Leo I. Gordon, Adam Yuh Lin, Reem Karmali, Shuo Ma, Barbara Pro, Jonathan Moreira

Blood (2022) 140 (Supplement 1): 6674–6675.

https://doi.org/10.1182/blood-2022-164724

Published: 2022

Journal Articles

Posttransplant Lymphoproliferative Disorder (PTLD) Following Transplantation at Northwestern University: Choice of Immunosuppressive Agents Does Not Impact Outcomes in PTLD

Megan Melody, Frederique St. Pierre, Irene Helenowski, William B Pearse, Chetan Vakkalagadda, Joseph R. Leventhal, Bing Ho, John Friedewald, Daniel Ganger, Jane N. Winter, Leo I. Gordon, Adam Yuh Lin, Reem Karmali, Shuo Ma, Barbara Pro, Jonathan Moreira

Blood (2022) 140 (Supplement 1): 3833–3834.

https://doi.org/10.1182/blood-2022-167812

Published: 2022

Journal Articles

Prognosis and Outcomes of Patients with Post-Transplant Lymphoproliferative Disorder: A Single Center Retrospective Review

William B Pearse, MD, Chetan V Vakkalagadda, MD, Irene Helenowski, PhD, Jane N. Winter, MD, Leo I. Gordon, MD, Reem Karmali, MDMSc, Shuo Ma, MD PhD, Joseph R. Leventhal, MD PhD, John Friedewald, MD, Daniel Ganger, MD, Barbara Pro, MD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-141286

Published: 2020

Journal Articles

A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib As Frontline Therapy for Patients with MYC-Aberrant Lymphoid Malignancies: The Daciphor Regimen

Carlos Galvez, MD, Reem Karmali, MDMSc, Mehdi Hamadani, MD, Leo I. Gordon, MD, Jane N. Winter, MD, Shuo Ma, MD PhD, Valerie Nelson, MD MBA, Brett Alan Palmer, BS, Timothy S. Fenske, MD, Nirav N. Shah, MD, Deepa Jagadeesh, MDMPH, Andreas Klein, MD, Irene Helenowski, PhD, Borko Jovanovic, PhD, Adam M Petrich, MD, Andrew M. Evens, DO,MMSc, Barbara Pro, MD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-138532

Published: 2020

Journal Articles

Sequential Brentuximab Vedotin (Bv) before and after Adriamycin, Vinblastine, and Dacarbazine (Bv-AVD) for Older Patients with Untreated Classical Hodgkin Lymphoma (cHL): Final Results from a Multicenter Phase II Study

Andrew M Evens, DO,MSc, Ranjana H. Advani, MD, Michelle A. Fanale, MD, Sonali M. Smith, MD, Irene Helenowski, PhD, Borko Jovanovic, PhD, R. Gregory Bociek, MD, Andreas Klein, MD, Jane N. Winter, MD, Leo I. Gordon, MD, Paul A. Hamlin, MD

Blood (2017) 130 (Supplement 1): 733.

https://doi.org/10.1182/blood.V130.Suppl_1.733.733

Published: 2017

Journal Articles

Disease Characteristics and Prognosis of Myelodysplastic Syndrome Presenting with Isolated Thrombocytopenia

Julie B Waisbren, MD, Shira N. Dinner, MD, Irene Helenowski, PhD, Juehua Gao, MDPhD, Brandon McMahon, MD, Brady Stein, MD

Blood (2015) 126 (23): 3477.

https://doi.org/10.1182/blood.V126.23.3477.3477

Published: 2015

Journal Articles

A Multicenter Phase II Study Of Bortezomib (VELCADE®) Combined With Rituximab For Untreated High Tumor Burden (HTB) Indolent Non-Hodgkin Lymphoma (NHL): Long-Term Follow-Up Of Outcomes and Examination Of Prognostic Factors

Andrew M Evens, DO, MSc, Mitchell R Smith, MD, PhD, Izidore S Lossos, MD, Irene Helenowski, PhD, Michael Millenson, MD, Jane N. Winter, MD, Steven T. Rosen, MD, FRCPA, Leo I. Gordon, MD

Blood (2013) 122 (21): 1807.

https://doi.org/10.1182/blood.V122.21.1807.1807

Published: 2013

Journal Articles

A Phase 2 Clinical Trial Adding Rituximab to CODOX-M/IVAC for Untreated Burkitts Lymphoma: Correlative Analysis of Serum and CSF Rituximab Levels

Andrew M. Evens, DO, MSc, Nahida Islam, MD, Kenneth R. Carson, MD, Victoria Browning, PhD, Chadi Nabhan, MD, FACP, Borko Jovanovic, PhD, Paul M. Barr, MD, Paolo F. Caimi, MD, Irene Helenowski, PhD, Stephanie A. Gregory, Jill Kolesar, PhD, Leo I. Gordon, MD

Blood (2012) 120 (21): 1640.

https://doi.org/10.1182/blood.V120.21.1640.1640

Published: 2012

Journal Articles

Trends in Incidence and Outcome in T-Cell Lymphoma Since 1992: A SEER Database Analysis

Adam M. Petrich, MD, Irene Helenowski, PhD, Robert W. Galamaga, DO, Chadi Nabhan, MD, FACP

Blood (2012) 120 (21): 4264.

https://doi.org/10.1182/blood.V120.21.4264.4264

Published: 2012

Journal Articles

A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era

Andrew M. Evens, Irene Helenowski, Erika Ramsdale, Chadi Nabhan, Reem Karmali, Britt Hanson, Benjamin Parsons, Scott Smith, Annette Larsen, June M. McKoy, Borko Jovanovic, Stephanie Gregory, Leo I. Gordon, Sonali M. Smith

Blood (2012) 119 (3): 692–695.

https://doi.org/10.1182/blood-2011-09-378414

Published: 2012

Includes: Supplemental data

Journal Articles

Multicenter Analysis of Elderly Hodgkin Lymphoma (eHL): Outcomes and Prognostic Factors in the Modern Era

Andrew M. Evens, DO, MSc, Irene Helenowski, MS, Chadi Nabhan, MD, FACP, Erika Ramsdale, MD, June M McKoy, MD, JD, MPH, MBA, Annette Larsen, B.A., R.N., Sarah Miyata, RN, MSN, ACNP, Benjamin Parsons, DO, Reem Karmali, MD, Britt E. Hanson, DO, Leo I. Gordon, MD, FACP, Scott E. Smith, MD, PhD, FACP, Stephanie A. Gregory, MD, Sonali M. Smith, MD

Blood (2011) 118 (21): 2625.

https://doi.org/10.1182/blood.V118.21.2625.2625

Published: 2011

Journal Articles

Integration of Rituximab and Liposomal Doxorubicin (DOXIL®) Into CODOX-M/IVAC for HIV-Negative and HIV+ Adults with Untreated Burkitt's Lymphoma (BL): Results of a Prospective Multicenter Phase II Study

Andrew M. Evens, DO, MSc, Kenneth R. Carson, MD, Chadi Nabhan, MD, FACP, Borko Jovanovic, PhD, Paul Barr, MD, Lilia Gallot, Irene Helenowski, MS, Paolo F. Caimi, MD, Stephanie A. Gregory, MD, Leo I. Gordon, MD, FACP

Blood (2011) 118 (21): 2669.

https://doi.org/10.1182/blood.V118.21.2669.2669

Published: 2011

Journal Articles

Multicenter Analysis of Very Elderly Indolent and Aggressive Non-Hodgkin Lymphoma (NHL): Impact of Functional Status on Outcome,

Chadi Nabhan, MD, FACP, Sonali M. Smith, MD, Irene Helenowski, MS, Erika Ramsdale, MD, Reem Karmali, MD, Benjamin Parsons, DO, Josephine L. Feliciano, MD, Britt E. Hanson, DO, Scott E. Smith, MD, PhD, FACP, Annette Larsen, B.A., R.N., June M. McKoy, MD, MPH, JD, MBA, Stephanie A. Gregory, MD, Andrew M. Evens, DO, MSc

Blood (2011) 118 (21): 3668.

https://doi.org/10.1182/blood.V118.21.3668.3668

Published: 2011

Journal Articles

A Phase I/II Trial of Combination Gemcitabine and Bortezomib (VELCADE®) for Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma (NHL) and Aggressive B-Cell NHL

Andrew M. Evens, DO, MSc, Steven T. Rosen, MD, FRCPA, Leo I. Gordon, MD, FACP, Irene Helenowski, MS, Justin Kline, MD, Annette Larsen, B.A., R.N., Jane N. Winter, M.D., Sonali M. Smith, MD, Koen M. Van Besien, MD

Blood (2011) 118 (21): 1646.

https://doi.org/10.1182/blood.V118.21.1646.1646

Published: 2011

Journal Articles

Multicenter Analysis of 150 Very Elderly Non-Hodgkin's Lymphoma (NHL) Patients: Impact of Comorbidities and Response to Initial Therapy on Survival

Andrew M Evens, DO, MSc, Chadi Nabhan, MD, FACP, Irene Helenowski, PhD, Annette Larsen, B.A., R.N., Erika E. Ramsdale, MD, Reem Karmali, MD, Josephine L. Feliciano, MD, Benjamin Parsons, MD, June M McKoy, MD, JD, MPH, MBA, Stephanie A. Gregory, MD, Sonali M Smith, MD

Blood (2010) 116 (21): 3124.

https://doi.org/10.1182/blood.V116.21.3124.3124

Published: 2010

Journal Articles

Pediatric Myelodysplastic Syndromes and Allogeneic Hematopoietic Progenitor Cell Transplantation (HPCT): A Single Center Perspective.

Jeffrey R. Andolina, MD, Morris Kletzel, MD, David Jacobsohn, MD, ScM, William T. Tse, MD, PhD, Jennifer Schneiderman, MD, MS, Reggie Duerst, MD, Irene Helenowski, Sonali Chaudhury, M.D.

Blood (2009) 114 (22): 1780.

https://doi.org/10.1182/blood.V114.22.1780.1780

Published: 2009

Journal Articles

Outcomes and a New Prognostic Model in Posttransplantation Lymphoproliferative Disorders (PTLD): Intent-to-Treat (ITT) Analysis of 81 Patients in the Post-Rituximab Era.

Andrew M. Evens, DO, MS, Kevin A. David, MD, Irene Helenowski, PhD, Sheetal M. Kircher, MD, Lauren Mauro, MD, Alla Gimelfarb, MD, Koen Van Besien, MD, Elise Hattersley, MD, Beverly P Nelson, MD, Jayesh Mehta, MD, Leo I. Gordon, MD, Jamile M. Shammo, MD, FASCP, Scott E. Smith, MD, PhD, Sonali Smith, MD

Blood (2008) 112 (11): 1776.

https://doi.org/10.1182/blood.V112.11.1776.1776

Published: 2008

Journal Articles

A Phase I/II Trial of Radioimmunotherapy (RIT) with 90 Yttrium-Ibritumomab Tiuxetan (Zevalin®; 90 Y-Zevalin) Combined with the Redox-Active Agent Motexafin Gadolinium (MGd): Prompt and High Remission Rates in Patients with Rituximab-Refractory Non-Hodgkin’s Lymphoma (NHL).

Andrew M. Evens, DO, MS, Stewart Spies, MD, David Patton, MS, Irene Helenowski, MS, Borko Jovanovic, PhD, Sarah Miyata, RN, ACNP, Elizabeth Hamilton, RN, CNP, M. Wayne Saville, MD, Richard A. Miller, MD, Jane N. Winter, MD, Leo I. Gordon, MD

Blood (2007) 110 (11): 2558.

https://doi.org/10.1182/blood.V110.11.2558.2558

Published: 2007

NARROW

Impact of Extranodal Disease Involvement on Outcomes in Post-Transplant Lymphoproliferative Disorder

Posttransplant Lymphoproliferative Disorder (PTLD) Following Transplantation at Northwestern University: Choice of Immunosuppressive Agents Does Not Impact Outcomes in PTLD

Prognosis and Outcomes of Patients with Post-Transplant Lymphoproliferative Disorder: A Single Center Retrospective Review

A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib As Frontline Therapy for Patients with MYC-Aberrant Lymphoid Malignancies: The Daciphor Regimen

Sequential Brentuximab Vedotin (Bv) before and after Adriamycin, Vinblastine, and Dacarbazine (Bv-AVD) for Older Patients with Untreated Classical Hodgkin Lymphoma (cHL): Final Results from a Multicenter Phase II Study

Disease Characteristics and Prognosis of Myelodysplastic Syndrome Presenting with Isolated Thrombocytopenia

A Multicenter Phase II Study Of Bortezomib (VELCADE®) Combined With Rituximab For Untreated High Tumor Burden (HTB) Indolent Non-Hodgkin Lymphoma (NHL): Long-Term Follow-Up Of Outcomes and Examination Of Prognostic Factors

A Phase 2 Clinical Trial Adding Rituximab to CODOX-M/IVAC for Untreated Burkitts Lymphoma: Correlative Analysis of Serum and CSF Rituximab Levels

Trends in Incidence and Outcome in T-Cell Lymphoma Since 1992: A SEER Database Analysis

A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era

Multicenter Analysis of Elderly Hodgkin Lymphoma (eHL): Outcomes and Prognostic Factors in the Modern Era

Integration of Rituximab and Liposomal Doxorubicin (DOXIL®) Into CODOX-M/IVAC for HIV-Negative and HIV+ Adults with Untreated Burkitt's Lymphoma (BL): Results of a Prospective Multicenter Phase II Study

Multicenter Analysis of Very Elderly Indolent and Aggressive Non-Hodgkin Lymphoma (NHL): Impact of Functional Status on Outcome,

A Phase I/II Trial of Combination Gemcitabine and Bortezomib (VELCADE®) for Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma (NHL) and Aggressive B-Cell NHL

Multicenter Analysis of 150 Very Elderly Non-Hodgkin's Lymphoma (NHL) Patients: Impact of Comorbidities and Response to Initial Therapy on Survival

Pediatric Myelodysplastic Syndromes and Allogeneic Hematopoietic Progenitor Cell Transplantation (HPCT): A Single Center Perspective.

Outcomes and a New Prognostic Model in Posttransplantation Lymphoproliferative Disorders (PTLD): Intent-to-Treat (ITT) Analysis of 81 Patients in the Post-Rituximab Era.

A Phase I/II Trial of Radioimmunotherapy (RIT) with 90 Yttrium-Ibritumomab Tiuxetan (Zevalin®; 90 Y-Zevalin) Combined with the Redox-Active Agent Motexafin Gadolinium (MGd): Prompt and High Remission Rates in Patients with Rituximab-Refractory Non-Hodgkin’s Lymphoma (NHL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only